Login to Your Account

Will the FDA balk at flexibility sacrifice in diabetes combos?

By Mari Serebrov
Regulatory Editor

Monday, May 23, 2016

As an FDA advisory committee prepares for a double header this week on two fixed-combination diabetes drugs, the agency seems to be balking a bit at the match-up of a basal insulin product that, when used alone, has a wide effective dose range with a GLP-1 receptor agonist that has only one or two recommended effective doses.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription